Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Economic impact associated with dronedarone use in patients with atrial fibrillation.
J Med Econ
January 2025
Sanofi, Bridgewater, NJ.
Objective/AimIn 2009, dronedarone was approved by the United States Food and Drug Administration based on results from the ATHENA trial (NCT00174785), which showed significant reduction of cardiovascular (CV) hospitalization and death in patients with atrial fibrillation (AF) randomized to dronedarone versus placebo. In 2020, a retrospective study by Goehring et al. showed CV hospitalizations and deaths were lower in clinical practice following initiation of dronedarone compared to other antiarrhythmic drugs (AADs) in patients with AF and atrial flutter.
View Article and Find Full Text PDFEnhanced Procedural Efficacy in Typical Atrial Flutter Ablation With a Visualizable Steerable Sheath.
Pacing Clin Electrophysiol
January 2025
Department of Cardiology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, P.R. China.
Objective: The Vizigo sheath, a novel visualizable steerable sheath, has been utilized effectively in the clinical management of atrial fibrillation. However, its application in the ablation of typical atrial flutter (AFL) remains unexplored. This study aims to evaluate and compare the efficacy and safety of the Vizigo sheath against a conventional fixed sheath during catheter ablation for typical AFL.
View Article and Find Full Text PDFPredictors of Arrhythmia Recurrence After Cryoballoon Ablation for Persistent Atrial Fibrillation: A Sub-Analysis of the Cryo Global Registry.
J Cardiovasc Electrophysiol
January 2025
Sakakibara Kinen Byoin, Fuchu, Japan.
Introduction: Freedom from recurrences of atrial tachyarrhythmia (ATA) is suboptimal after pulmonary vein isolation (PVI) in patients with persistent atrial fibrillation (PsAF). This sub-analysis from the Cryo Global Registry sought to investigate predictors of ablation success after PVI using cryoballoon ablation (CBA) for PsAF.
Methods And Results: ATA recurrence was defined as ≥ 30 s recurrence of atrial fibrillation, atrial flutter or atrial tachycardia after a 90-day blanking period and through 12-months.
Acute Nonsustained Mitral Isthmus Block Obtained With Sphere-9 Lattice-Tip Catheter Completed With Vein of Marshall Ethanol Infusion.
J Cardiovasc Electrophysiol
January 2025
Hôpital Cardiologique du Haut Léveque, CHU de Bordeaux, L'Institut de RYthmologie et modelisation Cardiaque (LIRYC), Université de Bordeaux, Bordeaux, France.
Background: Achieving a durable mitral line block using radiofrequency as a part of an anatomical approach for ablation in patients with persistent atrial fibrillation or for treating peri-mitral flutter has always been challenging due to the complex anatomy of the mitral isthmus. Epicardial ablation via the coronary sinus and the vein of Marshall has been proposed to help create durable lesions. Recently, a novel lattice-tip catheter using pulsed field ablation has shown promising results for creating mitral lines, despite limited data.
View Article and Find Full Text PDFAutonomic Nervous System Activity before Atrial Fibrillation Onset as Assessed by Heart Rate Variability.
Rev Cardiovasc Med
January 2025
Cardiology Department, Université de Mons, 7000 Mons, Belgium.
Background: Neuromodulation has been shown to increase the efficacy of atrial fibrillation (AF) ablation procedures. However, despite its ability to influence the autonomic nervous system (ANS), the exact mechanism of action remains unclear. The activity of the ANS via the intracardiac nervous system (ICNS) can be inferred from heart rate variability (HRV).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!